Detalles de la búsqueda
1.
Meta-analysis of the risk of autoimmune thyroiditis, Guillain-Barré syndrome, and inflammatory bowel disease following vaccination with AS04-adjuvanted human papillomavirus 16/18 vaccine.
Pharmacoepidemiol Drug Saf
; 29(9): 1159-1167, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32583515
2.
Six-year multi-centre, observational, post-marketing surveillance of the safety of the HPV-16/18 AS04-adjuvanted vaccine in women aged 10-25 years in Korea.
Pharmacoepidemiol Drug Saf
; 26(7): 837-842, 2017 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-28266092
3.
Impact of adjuvants on CD4(+) T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial.
Clin Immunol
; 169: 16-27, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27236001
4.
Signal detection based on time-to-onset: extending a new method from spontaneous reports to observational studies.
Pharmacoepidemiol Drug Saf
; 23(8): 849-58, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24946233
5.
Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience.
Pharmacoepidemiol Drug Saf
; 23(5): 456-65, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24644078
6.
A Model for Monitoring Spontaneously Reported Medication Errors Using the Adjuvanted Recombinant Zoster Vaccine as an Example.
Adv Pharmacol Pharm Sci
; 2024: 6435993, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38298461
7.
Safety and efficacy of recombinant and live herpes zoster vaccines for prevention in at-risk adults with chronic diseases and immunocompromising conditions.
Vaccine
; 41(1): 36-48, 2023 01 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36460534
8.
Harmonizing the collection of solicited adverse events in prophylactic vaccine clinical trials.
Expert Rev Vaccines
; 22(1): 849-859, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37750613
9.
Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study.
EClinicalMedicine
; 62: 102109, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37533419
10.
Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.
Lancet Infect Dis
; 22(5): 636-648, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35090638
11.
An Analysis of Spontaneously Reported Data of Vesicular and Bullous Cutaneous Eruptions Occurring Following Vaccination with the Adjuvanted Recombinant Zoster Vaccine.
Drug Saf
; 44(12): 1341-1353, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34622421
12.
Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials.
Drug Saf
; 44(7): 811-823, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34115324
13.
Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study.
Lancet Infect Dis
; 21(9): 1257-1270, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33887209
14.
Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology.
Drug Saf
; 43(12): 1223-1234, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32862397
15.
Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine.
Vaccine
; 38(18): 3489-3500, 2020 04 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-31818534
16.
Immunogenicity and safety of the AS04-HPV-16/18 and HPV-6/11/16/18 human papillomavirus vaccines in asymptomatic young women living with HIV aged 15-25 years: A phase IV randomized comparative study.
EClinicalMedicine
; 23: 100353, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32639485
17.
The how's and what's of vaccine reactogenicity.
NPJ Vaccines
; 4: 39, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31583123
18.
Adjuvant Systems for vaccines: 13â¯years of post-licensure experience in diverse populations have progressed the way adjuvanted vaccine safety is investigated and understood.
Vaccine
; 37(38): 5670-5680, 2019 09 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31420171
19.
Safety of AS03-adjuvanted influenza vaccines: A review of the evidence.
Vaccine
; 37(23): 3006-3021, 2019 05 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-31031030
20.
Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials.
Vaccine
; 37(18): 2482-2493, 2019 04 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-30935742